PMID- 22613649
OWN - NLM
STAT- MEDLINE
DCOM- 20120918
LR  - 20161125
IS  - 2542-5641 (Electronic)
IS  - 0366-6999 (Linking)
VI  - 125
IP  - 8
DP  - 2012 Apr
TI  - Effect of oxymatrine on specific cytotoxic T lymphocyte surface programmed death 
      receptor-1 expression in patients with chronic hepatitis B.
PG  - 1434-8
AB  - BACKGROUND: Oxymatrine has certain antiviral effects in the treatment of chronic 
      hepatitis B (CHB), but its exact mechanism is unclear. The objective of the 
      present study was to explore oxymatrine's antiviral mechanism by studying its 
      effect on the hepatitis B virus (HBV) specific cytotoxic T lymphocyte (CTL) 
      surface programmed death receptor-1 (PD-1) expression in CHB patients. METHODS: 
      Sixty-five CHB patients who had HBV DNA(3)10(4) copies/ml, positive HBeAg, 
      positive human leukocyte antigen (HLA)-A2, alanine aminotransferase (ALT) > 2 x 
      upper limit of normal value (ULN) were randomly divided into two groups: 
      treatment group (n = 33), treated with an intravenous infusion of 600 mg 
      oxymatrine in glucose solution once a day for a month, then with a 200 mg 
      oxymatrine oral capsule three times a day, and a 200 mg silibin meglumine tablet 
      three times a day; control group (n = 32) patients were treated only with silibin 
      meglumine tablet, method and dosage were the same as those of treatment group. 
      Three months later, peripheral blood HBV-specific CTL surface PD-1 expression, 
      HBV-specific CTL level, HBV DNA, HBeAg, and results of liver function tests were 
      analyzed and compared. RESULTS: Three months post-treatment, in the treatment 
      group, peripheral blood HBV-specific CTL surface PD-1 expression ((19.42 +/- 
      15.94)%) decreased significantly compared to the pretreatment level ((31.30 +/- 
      24.06)%; P < 0.05), and decreased significantly compared to that of control group 
      three months after treatment ((29.45 +/- 21.62)%; P < 0.05). HBV-specific CTL level 
      ((0.42 +/- 0.07)%) significantly increased compared with the pretreatment ((0.29 +/- 
      0.15)%; P < 0.01), and the control group posttreatment level was (0.31 +/- 0.15)% 
      (P < 0.05). HBV DNA level in 11 cases became negative (HBV DNA < 500 copies/ml, 
      33.33%), which was higher than that of the control group after treatment (two 
      cases, 6.25%; chi(2) = 7.45, P < 0.01), HBeAg of nine cases turned negative 
      (27.27%), which was higher than that of the control group after treatment (one 
      case, 3.13%; chi(2) = 7.27, P < 0.01). CONCLUSION: Oxymatrine could downregulate 
      peripheral blood HBV-specific CTL surface PD-1 expression in CHB patients, 
      increase HBV-specific CTL level, which may be one of the possible mechanisms by 
      which oxymatrine clears or inhibits HBV in CHB patients.
FAU - Gu, Xi-bing
AU  - Gu XB
AD  - Department of Hepatology, Wuxi Hospital for Infectious Diseases, Wuxi, Jiangsu 
      214005, China. gxb188681@sina.com
FAU - Yang, Xiao-juan
AU  - Yang XJ
FAU - Hua, Zhong
AU  - Hua Z
FAU - Lu, Zhong-hua
AU  - Lu ZH
FAU - Zhang, Bo
AU  - Zhang B
FAU - Zhu, Yin-fang
AU  - Zhu YF
FAU - Wu, Hang-yuan
AU  - Wu HY
FAU - Jiang, Yi-ming
AU  - Jiang YM
FAU - Chen, Hao-kun
AU  - Chen HK
FAU - Pei, Hao
AU  - Pei H
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - China
TA  - Chin Med J (Engl)
JT  - Chinese medical journal
JID - 7513795
RN  - 0 (Alkaloids)
RN  - 0 (Antiviral Agents)
RN  - 0 (DNA, Viral)
RN  - 0 (PDCD1 protein, human)
RN  - 0 (Programmed Cell Death 1 Receptor)
RN  - 0 (Quinolizines)
RN  - 85U4C366QS (oxymatrine)
SB  - IM
MH  - Adult
MH  - Alkaloids/*therapeutic use
MH  - Antiviral Agents/*therapeutic use
MH  - DNA, Viral/blood
MH  - Female
MH  - Hepatitis B virus/immunology
MH  - Hepatitis B, Chronic/*drug therapy/immunology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Programmed Cell Death 1 Receptor/*analysis
MH  - Quinolizines/*therapeutic use
MH  - T-Lymphocytes, Cytotoxic/*chemistry
EDAT- 2012/05/23 06:00
MHDA- 2012/09/19 06:00
CRDT- 2012/05/23 06:00
PHST- 2012/05/23 06:00 [entrez]
PHST- 2012/05/23 06:00 [pubmed]
PHST- 2012/09/19 06:00 [medline]
PST - ppublish
SO  - Chin Med J (Engl). 2012 Apr;125(8):1434-8.